Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide

This study provides real-world evidence of the cardiovascular risk of AA and ENZ that may not appear in clinical trial settings. Adjusting for age, baseline comorbidities, and SES, the likelihood of a cardiovascular event did not differ between treatment groups.PMID:38591349 | DOI:10.2340/1651-226X.2024.20337

Source: Acta Oncologica - April 9, 2024 Category: Cancer & Oncology Authors: Onur Baser Gabriela Samayoa Archana Dwivedi Sara AlSaleh Burhan Cigdem Erdi Kizilkaya Source Type: research